New hope for Alzheimer's agitation: experimental drugs aim to soothe without sedation
Symptom relief
Recruiting now
This study tests two experimental drugs, EXV-802 and EXV-801, to see if they can safely reduce agitation in people with Alzheimer's disease. About 300 participants aged 55 to 90 with moderate to severe agitation will receive either the drug or a placebo for 6 weeks. The goal is t…
Phase: PHASE2, PHASE3 • Sponsor: Exciva GmbH • Aim: Symptom relief
Last updated Jun 15, 2026 18:55 UTC